Arcutis Biotherapeutics Inc
ARQT14.340USD
+0.050+0.35%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.71BCap. mercado
PérdidaP/E TTM
Más Datos de Arcutis Biotherapeutics Inc Compañía
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Información de la empresa
Símbolo de cotizaciónARQT
Nombre de la empresaArcutis Biotherapeutics Inc
Fecha de salida a bolsaJan 31, 2020
Director ejecutivoMr. Todd Franklin Watanabe
Número de empleados342
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección3027 Townsgate Road
CiudadWESTLAKE VILLAGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal91361
Teléfono18054185006
Sitio Webhttps://arcutis.com/
Símbolo de cotizaciónARQT
Fecha de salida a bolsaJan 31, 2020
Director ejecutivoMr. Todd Franklin Watanabe
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
721.32K
-0.28%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
-8.42%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
78.26K
-8.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.10K
--
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
26.43K
+40.42%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
23.36K
+48.32%
Ms. Terrie J. Curran
Ms. Terrie J. Curran
Independent Director
Independent Director
--
--
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
721.32K
-0.28%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
-8.42%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
78.26K
-8.03%
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.10K
--
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Suvretta Capital Management, LLC
9.58%
Jennison Associates LLC
9.32%
Rubric Capital Management LP
9.20%
Frazier Life Sciences Management, L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
6.63%
Other
57.89%
Accionistas
Accionistas
Proporción
Suvretta Capital Management, LLC
9.58%
Jennison Associates LLC
9.32%
Rubric Capital Management LP
9.20%
Frazier Life Sciences Management, L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
6.63%
Other
57.89%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
32.24%
Investment Advisor/Hedge Fund
31.96%
Hedge Fund
29.96%
Private Equity
7.39%
Research Firm
4.30%
Individual Investor
2.19%
Venture Capital
1.84%
Sovereign Wealth Fund
0.45%
Bank and Trust
0.42%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
477
132.39M
111.07%
-21.95M
2025Q1
487
132.87M
111.51%
-24.00M
2024Q4
453
136.04M
114.96%
-23.73M
2024Q3
433
136.12M
116.66%
-19.10M
2024Q2
416
134.94M
116.78%
-20.37M
2024Q1
392
131.83M
115.81%
+2.26M
2023Q4
366
104.30M
108.66%
+5.22M
2023Q3
364
79.57M
131.78%
-15.32M
2023Q2
359
84.02M
139.44%
-6.66M
2023Q1
352
83.59M
140.11%
+3.40M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Suvretta Capital Management, LLC
11.42M
9.58%
+23.84K
+0.21%
Mar 31, 2025
Jennison Associates LLC
11.36M
9.53%
-978.92K
-7.93%
Mar 31, 2025
Rubric Capital Management LP
10.97M
9.2%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
8.79M
7.37%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.91M
6.63%
-197.41K
-2.44%
Mar 31, 2025
The Vanguard Group, Inc.
6.79M
5.7%
+373.66K
+5.82%
Mar 31, 2025
Polar Capital LLP
6.71M
5.63%
-670.91K
-9.09%
Mar 31, 2025
State Street Global Advisors (US)
4.47M
3.75%
-476.52K
-9.63%
Mar 31, 2025
Gilder Gagnon Howe & Co. LLC
4.10M
3.44%
+193.06K
+4.95%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.08M
2.58%
-403.45K
-11.59%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Simplify Health Care ETF
4.4%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
SPDR S&P Biotech ETF
0.55%
First Trust Small Cap Growth AlphaDEX Fund
0.49%
Direxion Daily S&P Biotech Bull 3X Shares
0.31%
Federated Hermes MDT Small Cap Core ETF
0.28%
First Trust Small Cap Core Alphadex Fund
0.27%
ProShares Ultra Nasdaq Biotechnology
0.19%
Invesco Nasdaq Biotechnology ETF
0.19%
Inspire Small/Mid Cap ESG ETF
0.17%
Ver más
Simplify Health Care ETF
Proporción4.4%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.93%
SPDR S&P Biotech ETF
Proporción0.55%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.49%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.31%
Federated Hermes MDT Small Cap Core ETF
Proporción0.28%
First Trust Small Cap Core Alphadex Fund
Proporción0.27%
ProShares Ultra Nasdaq Biotechnology
Proporción0.19%
Invesco Nasdaq Biotechnology ETF
Proporción0.19%
Inspire Small/Mid Cap ESG ETF
Proporción0.17%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
